Loading...

PE/Cyanine7 anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_EH12dot2H7_PECy7_092809
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE/Cyanine7 (filled histogram) or mouse IgG1, κ PE/Cyanine7 (open histogram).
  • A_EH12dot2H7_PECy7_092809
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE/Cyanine7 (filled histogram) or mouse IgG1, κ PE/Cyanine7 (open histogram).
  • B_EH12dot2H7_PeCy7_100609
    Human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE/Cyanine7 and CD3 (clone UCHT1) FITC.
See PE/Cyanine7 spectral data
Cat # Size Price Save
329917 25 tests ¥38,720
329918 100 tests ¥84,040
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Gordon-Alonso M,et al. 2017. Nat. Commun. 10.1038/s41467-017-00925-6. PubMed
  2. Kuo HH, et al. 2018. Immunity. 48:1183. PubMed
  3. Tardif V, et al. 2019. Nat Commun. 10:823. PubMed
  4. Chellappa S, et al. 2019. J Immunol. 202:1397. PubMed
  5. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  6. Colleen S McGary et al. 2017. Immunity. 47(4):776-788 . PubMed
  7. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  8. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  9. Barili V, et al. 2020. Nat Commun. 0.877777778. PubMed
  10. Hu JQ, et al. 2020. J Cancer. 3.409722222. PubMed
  11. Yoshitomi H, et al. 2018. Nat Commun. 2.9875. PubMed
  12. Beltra JC, et al. 2020. Immunity. 52(5):825-841. PubMed
  13. Hong J, et al. 2012. J Immunol. 188:3247. PubMed
  14. Amancha P, et al. 2013. J Immunol. 191:6060. PubMed
  15. Hong J, et al. 2014. J Immunol. 193:797. PubMed
  16. Ohue Y, et al. 2014. Clin Cancer Res. 20:5052. PubMed
  17. Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed
  18. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  19. Policicchio B, et al. 2016. PLoS Pathog. 12: 1005879. PubMed
  20. Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed
  21. Parsons E, et al. 2016. PLoS One. 11:e0167841. PubMed
  22. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  23. Tang X, et al. 2020. Sci Adv. 6:eaaz0374. PubMed
  24. Lee J, et al. 2020. Sci Rep. 10:17753. PubMed
  25. Zhou J, et al. 2020. Oncol Lett. 1.336111111. PubMed
  26. Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
  27. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  28. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  29. Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed
  30. Brudno JN, et al. 2020. Nat Med. 270:26. PubMed
  31. Chen Y, et al. 2020. Cell. 1496:183. PubMed
  32. Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed
  33. Dart SJ, et al. 2021. Sci Rep. 11:15312. PubMed
  34. Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
  35. Shen C, et al. 2021. Front Immunol. 12:680055. PubMed
  36. Verma A, et al. 2021. Cell Rep. 37:109942. PubMed
  37. Khanam A, et al. 2021. Front Immunol. 11:599648. PubMed
  38. Rnjak D, et al. 2021. Transfus Clin Biol. . PubMed
  39. Dehmani S, et al. 2021. Front Immunol. 12:732530. PubMed
  40. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  41. Lederer K, et al. 2022. Cell. . PubMed
  42. Au L, et al. 2021. Cancer Cell. 39:1497. PubMed
  43. Den Braanker H, et al. 2021. Front Immunol. 12:768113. PubMed
  44. Wildner NH, et al. 2022. Front Immunol. 13:886646. PubMed
  45. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  46. Csomós K, et al. 2022. Nat Immunol. 23:1256. PubMed
  47. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  48. Olwenyi OA, et al. 2020. Cells. 9:. PubMed
  49. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  50. Bettini E, et al. 2022. STAR Protoc. 3:101840. PubMed
RRID
AB_2159325 (BioLegend Cat. No. 329917)
AB_2159324 (BioLegend Cat. No. 329918)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 01/22/2015

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account